Publicacións en colaboración con investigadores/as de Novartis (Sweden) (8)

2021

  1. Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: Results from the REUMAVID study (phase 1)

    RMD Open, Vol. 7, Núm. 1

  2. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

    Rheumatology (United Kingdom), Vol. 60, Núm. 1, pp. 256-262

  3. Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 5, pp. 582-590

2017

  1. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator– and Placebo-Controlled Study

    Arthritis and Rheumatology, Vol. 69, Núm. 6, pp. 1144-1153

2011

  1. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study

    BMC Musculoskeletal Disorders, Vol. 12

2010

  1. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis

    Science Translational Medicine, Vol. 2, Núm. 52

2001

  1. Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural α-Galactosyl IgG antibodies

    Xenotransplantation, Vol. 8, Núm. 1, pp. 15-23

1999

  1. Sustained decrease of serum anti-galactose α1-3-galactose antibodies in baboons by removing aerobic gram-negative bacteria from the bowel

    Transplantation Proceedings